|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600120278 |
|
最近更新日期: Date of Last Refreshed on: |
2026-03-11 15:56:25 |
|
注册时间: Date of Registration: |
2026-03-11 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
復發性眼部單純疱疹病毒疾病患者的生活質素與病人自述結果:一項前瞻性橫斷面研究 |
|
Public title: |
Quality of Life and Patient Reported Outcome Measures in Patients with Recurrent Ocular HSV Disease: A Prospective Cross-sectional Study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
復發性眼部單純疱疹病毒疾病患者的生活質素與病人自述結果:一項前瞻性橫斷面研究 |
|
Scientific title: |
Quality of Life and Patient Reported Outcome Measures in Patients with Recurrent Ocular HSV Disease: A Prospective Cross-sectional Study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
Jennifer Tsoi |
研究负责人: |
陳欣遇 |
|
Applicant: |
Jennifer Tsoi |
Study leader: |
Julia Yan Yu CHAN |
|
申请注册联系人电话: Applicant telephone: |
+852 3943 5818 |
研究负责人电话:
Study leader's |
+852 3943 5829 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
jennifertsoi@cuhk.edu.hk |
研究负责人电子邮件: Study leader's E-mail: |
juliachan@cuhk.edu.hk |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
香港九龍旺角亞皆老街147K香港眼科醫院3樓 |
研究负责人通讯地址: |
香港九龍旺角亞皆老街147K香港眼科醫院4樓 |
|
Applicant address: |
3/F, Hong Kong Eye Hospital, 147K Argyle Street, Kowloon, Hong Kong SAR |
Study leader's address: |
4/F, Hong Kong Eye Hospital, 147K Argyle Street, Kowloon, Hong Kong SAR |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
香港中文大學眼科與視覺科學系 |
||
|
Applicant's institution: |
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong |
||
|
研究负责人所在单位: |
香港中文大學眼科與視覺科學系 |
||
|
Affiliation of the Leader: |
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
CIRB-2024-245-3 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
醫院管理局中央研究倫理委員會 |
||
|
Name of the ethic committee: |
Hospital Authority Central Institutional Review Board (Central IRB) |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-07-31 00:00:00 | ||
|
伦理委员会联系人: |
Ms Mandy Luk |
||
|
Contact Name of the ethic committee: |
Ms Mandy Luk |
||
|
伦理委员会联系地址: |
九龍亞皆老街147C號衞生防護中心5樓A座A503室 |
||
|
Contact Address of the ethic committee: |
A503, 5/F, Block A, Centre for Health Protection, 147C Argyle Street, Kowloon |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+852 2300 8472 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
香港中文大學眼科與視覺科學系 |
||||||||||||||||||||||
|
Primary sponsor: |
Department of Ophthalmology and Visual Sciences, CUHK |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
九龍亞皆老街147K號 香港眼科醫院3樓 |
||||||||||||||||||||||
|
Primary sponsor's address: |
3/F, Hong Kong Eye Hospital, 147K Argyle Street, Kowloon, Hong Kong |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
部門經費 |
||||||||||||||||||||||
|
Source(s) of funding: |
Departmental funding |
||||||||||||||||||||||
|
研究疾病: |
眼部單純疱疹病毒 (HSV) 疾病 |
||||||||||||||||||||||
|
Target disease: |
Ocular Herpes Simplex Virus (HSV) Disease |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
比較和對照復發性眼部單純疱疹病毒HSV疾病患者在病毒活動期和潛伏期的病人自述結果 (PROMs)和生活品質(QoL)。 |
||||||||||||||||||||||
|
Objectives of Study: |
To compare and contrast the PROMs and QoL of patients with recurrent ocular HSV disease during the active and latent phases. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 願意參與本研究並能提供知情同意的患者; 2. 年齡滿 18 歲或以上; 3. 在過去 5 年內,曾至少一隻眼患過一次經臨床確認的眼部 HSV 疾病(即眼瞼炎、結膜炎、上皮型角膜炎、基質型角膜炎或虹膜炎); 4. 具備足夠的認知能力,能理解並完成研究問卷。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Patients who are willing to participate in the study and able to give informed consent; 2. Age 18 years or above; 3. Have had at least one episode of clinically confirmed ocular HSV disease (i.e., blepharitis,conjunctivitis, epithelial keratitis, stromal keratitis, or iritis) in one eye within the preceding 5 years; 4. Possess adequate cognitive ability to understand and complete the study questionnaires. |
||||||||||||||||||||||
|
排除标准: |
1. 非 HSV 相關但會嚴重影響視功能及視覺相關生活品質之眼部疾病,包括但不限於晚期青光眼、老年黃斑變性、晚期白內障; 2. 正在患非 HSV 病因引起的眼部感染(例如:細菌性、黴菌性或棘阿米巴角膜炎); 3. 在過去 6 個月內曾接受角膜或眼內手術的病史; 4. 有眼部水痘帶狀疱疹病毒疾病之病史; 5. 無法可靠地完成研究問卷(例如因認知障礙)。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Ocular diseases unrelated to HSV that significantly affect patients’ visual function and vision-related quality of life, including but not limited to advanced glaucoma, age-related macular degeneration, advanced cataract; 2. Active ocular infection of non-HSV etiology (e.g., bacterial, fungal, or acanthamoeba keratitis); 3. History of recent corneal or intraocular surgery within the preceding 6 months; 4. Documented history of ocular Varicella Zoster Virus disease; 5. Inability to reliably complete the study questionnaires (e.g., due to cognitive impairment). |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-04-01 00:00:00至 To 2028-03-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-03-20 00:00:00 至 To 2028-03-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
N/A |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
N/A |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
電子數據將只在我們安全的研究室電腦內保存,並受到密碼保護。這項研究的資料將給予香港中文大學醫學院眼科及視覺科學學系進行統計分析。您的身份將受嚴格保密,只有整體的結果將被公佈。個人資料將於研究完結後保存五年,數據和血液樣本將根據醫院管理局的政策銷毀。於任何時間,您可要求銷毀所有相關的研究結果和記錄。簽署知情同意書的同時,亦表示您允許臨床研究倫理委員會及有關法定機構在合適的條例及法例容許下及在不侵犯您的私隱情況中,直接翻查您的研究記錄以核實臨床研究計劃之程序和/或數據。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic data will be only saved in physically-secured and password-protected computers in our research office. Information from this study will be submitted to the Department of Ophthalmology & Visual Sciences, the Chinese University of Hong Kong for statistical analysis. Only the overall result will be published and your identity will remain confidential. Personal data will be kept for 5 years after the study. The data as well as blood samples will be destructed according to policies of the Hospital Authority. Records and results of all study investigations can be destroyed on your request in future. By signing a written informed consent form, you are authorizing the Research Ethics Committee (REC) and the regulatory authority(ies) a direct access to your original research records for verification of clinical trial procedures and/or data, without violating your confidentiality, to the extent permitted by the applicable laws and regulations. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |